<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179803</url>
  </required_header>
  <id_info>
    <org_study_id>BMT 0398</org_study_id>
    <nct_id>NCT00179803</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors</brief_title>
  <official_title>Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to determine if a stem cell transplant in patients with&#xD;
      newly diagnosed high risk CNS tumors (glioblastoma multiforme [GBM], high grade astrocytoma,&#xD;
      pineoblastoma, rhabdoid tumor, supratentorial primitive neuroectodermal tumor [PNET])&#xD;
      increases overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>high dose chemotherapy with stem cell rescue thiotepa, carboplatin &amp; etoposide</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors</measure>
    <time_frame>To end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation.</measure>
    <time_frame>To end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy.</measure>
    <time_frame>To end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the long term neurocognitive, endocrinologic, cardiopulmonary, and hematologic sequelae of sequential myeloablative chemotherapy and stem cell rescues in patients treated for high risk CNS and recurrent CNS tumors.</measure>
    <time_frame>To end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the feasibility and utility of the myeloablative preparatory regimen of Carboplatinum, VP-16 and Thiotepa administered in an outpatient setting, and to determine the cost savings obtained via this strategy.</measure>
    <time_frame>To end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Astrocytoma</condition>
  <condition>Pineoblastoma</condition>
  <condition>Rhabdoid Tumor</condition>
  <condition>Supratentorial Neoplasms</condition>
  <arm_group>
    <arm_group_label>high dose chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Group A: recurrent medulloblastoma, recurrent germ cell tumor&#xD;
Cytoxan treatment&#xD;
Stem cell autologous harvest&#xD;
Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET&#xD;
Carboplatin and Etoposide treatment&#xD;
Autologous stem cell harvest&#xD;
The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to &gt;1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue.</description>
    <arm_group_label>high dose chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient's age must be greater than (&gt;) 18 months and less than or equal to (â‰¤) 25&#xD;
             years at the time of diagnosis or recurrence.&#xD;
&#xD;
          -  Neuroradiographic evidence of a recurrent posterior fossa medulloblastoma or recurrent&#xD;
             CNS germ cell tumor.&#xD;
&#xD;
          -  The presence of a histologically confirmed high grade astrocytoma, GBM, rhabdoid&#xD;
             tumor, supratentorial PNET, or pineoblastoma either at the time of diagnosis or&#xD;
             recurrence.&#xD;
&#xD;
          -  Patients must be brought to state of minimum residual disease by surgical reduction&#xD;
             and/or chemotherapy and/or radiation therapy or a combination of above prior to&#xD;
             myeloablative chemotherapy and tandem stem cell rescue.&#xD;
&#xD;
          -  Documentation of chemotherapy sensitivity is required for enrollment.&#xD;
             Chemotherapy-sensitive tumors are defined as those tumors which have had a reduction&#xD;
             of 50% after 2-4 cycles of chemotherapy (CTX or platinum). For patients with no&#xD;
             evidence of disease post resection, continued complete remission after 2-4 cycles of&#xD;
             chemotherapy defines chemosensitivity.&#xD;
&#xD;
          -  Adequate physiologic function, defined as follows:&#xD;
&#xD;
               -  creatinine clearance &gt; 70 ml/minutes/1.73 m2.&#xD;
&#xD;
               -  SGPT &lt; 10 x normal and bilirubin &lt; 10 mg/dl.&#xD;
&#xD;
          -  Adequate complete blood count (CBC): hemoglobin &gt; 10 gm/dl, absolute neutrophil count&#xD;
             (ANC) &gt; 1500/ul, and platelets &gt; 100,000/ul.&#xD;
&#xD;
          -  Informed consent. The patient and/or the patient's legally authorized guardian must&#xD;
             acknowledge in writing that consent to become a study subject has been obtained, in&#xD;
             accordance with institutional policies provided by the United States (U.S.) Department&#xD;
             of Health and Human Services.&#xD;
&#xD;
          -  Protocol approval. Approval for the use of this institution's Human Rights Committee&#xD;
             must be obtained in accordance with the institutional assurance policies of the U. S.&#xD;
             Department of Health and Human Services.&#xD;
&#xD;
          -  Patients with high-risk medulloblastoma after initial surgery.&#xD;
&#xD;
          -  To allow non-English speaking patients to participate in this study, bilingual health&#xD;
             care services will be provided in the appropriate language.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with brain stem glioma are ineligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stewart Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Stewart Goldman</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>brain tumor</keyword>
  <keyword>medulloblastoma</keyword>
  <keyword>germ cell tumor</keyword>
  <keyword>CNS tumor</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>astrocytoma</keyword>
  <keyword>pineoblastoma</keyword>
  <keyword>rhabdoid tumor</keyword>
  <keyword>supratentorial PNET</keyword>
  <keyword>high grade astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Supratentorial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

